Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 2
1960 3
1961 2
1963 4
1964 4
1965 2
1966 1
1967 1
1969 4
1970 2
1971 2
1972 5
1973 2
1974 4
1975 5
1976 10
1977 5
1978 10
1979 9
1980 7
1981 6
1982 4
1983 7
1984 17
1985 14
1986 9
1987 5
1988 11
1989 4
1990 10
1991 11
1992 8
1993 11
1994 16
1995 17
1996 17
1997 10
1998 9
1999 9
2000 9
2001 20
2002 16
2003 17
2004 20
2005 34
2006 41
2007 44
2008 59
2009 73
2010 88
2011 113
2012 151
2013 139
2014 149
2015 131
2016 132
2017 157
2018 141
2019 161
2020 175
2021 136
Text availability
Article attribute
Article type
Publication date

Search Results

2,027 results
Results by year
Filters applied: . Clear all
Page 1
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. Saura C, et al. Among authors: yeh ym. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. J Clin Oncol. 2020. PMID: 32678716 Free PMC article. Clinical Trial.
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy.
Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. Tan KT, et al. Among authors: yeh yc. J Immunother Cancer. 2020 Mar;8(1):e000485. doi: 10.1136/jitc-2019-000485. J Immunother Cancer. 2020. PMID: 32238472 Free PMC article.
Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target.
Liu R, Yeh YJ, Varabyou A, Collora JA, Sherrill-Mix S, Talbot CC Jr, Mehta S, Albrecht K, Hao H, Zhang H, Pollack RA, Beg SA, Calvi RM, Hu J, Durand CM, Ambinder RF, Hoh R, Deeks SG, Chiarella J, Spudich S, Douek DC, Bushman FD, Pertea M, Ho YC. Liu R, et al. Among authors: yeh yj. Sci Transl Med. 2020 May 13;12(543):eaaz0802. doi: 10.1126/scitranslmed.aaz0802. Sci Transl Med. 2020. PMID: 32404504 Free PMC article.
2,027 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page